Patrick Riddle, MD
Ophthalmology · Nashua, NHNPI 1811992993
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 189 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations.
Across 189 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$539
- Bausch & Lomb Americas Inc.$493
- AbbVie$436
- Amgen$434
- Oyster Point Pharma, Inc.$312
- Bausch & Lomb, A Division Of Bausch Health US, LLC$265
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,094100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 18 | $539 |
| Bausch & Lomb Americas Inc. | 23 | $493 |
| AbbVie(2 entities) | 20 | $436 |
| Amgen(2 entities) | 24 | $434 |
| Oyster Point Pharma, Inc. | 19 | $312 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $265 |
| Aerie Pharmaceuticals, Inc. | 13 | $240 |
| Astellas Pharma US Inc | 8 | $211 |
| Kala Pharmaceuticals, Inc. | 9 | $181 |
| Novartis | 8 | $164 |
| Mallinckrodt Hospital Products Inc. | 5 | $157 |
| Dompe US, Inc. | 4 | $127 |
| Sun Pharmaceutical Industries Inc. | 6 | $94 |
| Apellis Pharmaceuticals, Inc. | 5 | $91 |
| Iridex Corporation | 1 | $70 |
| Rayner Intraocular Lenses Limited | 2 | $40 |
| Johnson & Johnson Vision Care, Inc. | 2 | $39 |
| Tarsus Pharmaceuticals, Inc. | 1 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Glaukos Corporation | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Coopervision Inc. | 1 | $24 |
| Vyera Pharmaceuticals, LLC | 1 | $22 |
| Sight Sciences, Inc. | 1 | $20 |
| Omeros Corporation | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,094 in reported general payments places this provider in the 80th percentile of 80 ophthalmology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 24 | $30,631 |
| Cyclosporine | 12 | $5,009 |
| Travoprost | 13 | $2,720 |
| TafluprostTafluprost/Pf | 12 | $1,508 |
| Latanoprost | 146 | $1,476 |
| Brimonidine Tartrate | 41 | $1,228 |
| Timolol Maleate | 88 | $1,027 |
| Prednisolone Acetate | 16 | $523 |
| Dorzolamide Hcl | 28 | $327 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 28 | $267 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $196 |
| Ofloxacin | 20 | $159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $436 | $30,63124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 80 ophthalmology providers in New Hampshire.
Other ophthalmology in Nashua
- John DagianisNashua$9K
- Timothy BlakeNashua$5K
- Faith BirnbaumNashua$4K
- Purak ParikhNashua$2K
- Charles WingateNashua$2K
- Dane SlentzDerry$127K
- Jason SzelogPortsmouth$71K
- Andrew CatomerisLebanon$56K
- Jennifer LingPortsmouth$9K
- Mohamed GuenenaDerry$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.